

CLEOPATRAX FOUNDER DR. RHONDA VOSKUHL FEATURED IN *THE NEW YORK TIMES* FOR ADVANCING ESTROGEN-BASED BRAIN THERAPIES

April 22, 2025 – Los Angeles, CA — CleopatraRX™ is proud to announce that Dr. Rhonda Voskuhl, founder and medical advisor to CleopatraRX™ and inventor of PearlPAK®, was prominently featured in *The New York Times* article titled “Sex Hormones Are Brain Hormones: What Does This Mean for Treating Brain Diseases?” The article spotlights the groundbreaking research reshaping how medicine understands the role of estrogen—not just as a reproductive hormone, but as a critical regulator of brain health.

Dr. Voskuhl, a neurologist at the University of California, Los Angeles, was interviewed alongside some of the most influential figures in brain and hormone research, including:

- Dr. Roberta Brinton, neuroscientist who leads the Center for Innovation in Brain Science at the University of Arizona.
- Dr. Lisa Mosconi, neuroscientist who directs the Women’s Brain Initiative at Weill Cornell Medicine.
- Dr. JoAnn Manson, a Women’s Health Initiative investigator and neuroendocrinologist at Brigham and Women’s Hospital.
- Dr. Hyman Schipper, neurologist at McGill University
- Dr. Jelena Pavlovic, neurologist at Albert Einstein College of Medicine

The Times reported on how Dr. Voskuhl has led decades of research into the neurological impacts of estrogen, which revealed that estriol, a form of estrogen produced during pregnancy, has profound neuroprotective properties by targeting a distinct estrogen receptor in brain. It reduced relapses in multiple sclerosis (MS), improving cognition, and preventing brain atrophy in clinical trials. “You’ve got to add something directly targeting the brain,” Dr. Voskuhl told *The Times*, explaining the need to go beyond anti-inflammatory treatments for MS.

Her breakthrough led to the development of **PearlPAK®**, a patented hormone therapy now offered through CleopatraRX™, which applies this research to cognitive decline associated with menopause in otherwise healthy women. 70% of menopausal women have cognitive issues, and there has been no treatment designed to for this. With traditional research and funding timelines failing to meet urgent patient needs, Dr. Voskuhl has initiated real-world monitoring of PearlPAK’s cognitive benefits using annual testing protocols. “I’m just taking the way we do things in M.S. and trying to apply it to menopause,” she said.

Dr. Voskuhl also emphasized the importance of interdisciplinary collaboration between hormone and brain specialists, warning that siloed medical approaches leave women underserved: “The answers are there,” she stated. “If they talk to each other, the answers are there.”

CleopatraRX™ is honored to support Dr. Voskuhl’s mission to bring cutting-edge science directly to the women who need it most. PearlPAK® represents a first-of-its-kind treatment designed to address menopause-related brain fog and cognitive changes—delivering evidence-based care to women in midlife and beyond.

Read the full *New York Times* feature:

<https://www.nytimes.com/2025/04/22/health/neuroscience-estrogen-hormones.html>

For media inquiries or to schedule an interview with Dr. Voskuhl, please contact:

marketing@cleopatrarx.com